|Articles|May 9, 2017
WIRB-Copernicus Acquires Again
WIRB-Copernicus Group (WCG) has announced the acquisition of MedAvante and ProPhase, and has named Dr. Jeffrey Litwin as CEO of the combined organization.
Advertisement
WIRB-Copernicus Group (WCG) has announced the acquisition of MedAvante and ProPhase, and has named Dr. Jeffrey Litwin as CEO of the combined organization. This acquisition provides WCG’s clients with a more comprehensive and integrated suite of study start-up solutions.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced
2
Breaking the Efficacy Ceiling in IBD and Beyond
3
ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps
4
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
5